Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. By leveraging genetic insights, Praxis aims to address conditions ranging from major depressive disorder to epilepsy.
The company's lead product candidates include:
- Prax-114: An extrasynaptic-preferring GABAA receptor positive allosteric modulator, currently in Phase IIa trials for treating major depressive disorder and perimenopausal depression.
- Prax-944: A selective small molecule inhibitor of T-type calcium channels, in Phase IIa trials for essential tremor treatment.
- Prax-562: A persistent sodium current blocker in Phase I trials aimed at severe pediatric epilepsy and adult cephalgia.
- Prax-222 (Elsunersen): An antisense oligonucleotide targeting gain-of-function SCN2A epilepsy, under collaboration with Ionis Pharmaceuticals and RogCon, Inc.
- PRAX-628: A next-gen small molecule targeting sodium-channels in the brain, being developed as a treatment for focal epilepsy.
- Ulixacaltamide: A small molecule inhibitor for essential tremor, currently in late-stage development.
Recent news highlights include a partnership with Tenacia to extend ulixacaltamide's reach to Greater China, and advances in the PRAX-628 program demonstrating its potential as a best-in-class epilepsy drug.
Financially, Praxis has shown significant progress. As of the latest reports, the company has sufficient funding to continue operations into 2027, driven by strategic public offerings and a lean operational model.
For more details, visit www.praxismedicines.com and follow them on social media channels.
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced the pricing of its underwritten public offering of 3,168,275 shares of its common stock at a public offering price per share of $35.50, with expected gross proceeds of approximately $150.0 million. The offering also includes pre-funded warrants to purchase up to an aggregate of 1,056,725 shares of common stock at a purchase price of $35.4999 per pre-funded warrant. The underwriters have been granted a 30-day option to purchase up to 633,750 additional shares of common stock at the public offering price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.66%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced a proposed public offering of its common stock and prefunded warrants to purchase shares of common stock. The offering, subject to market conditions, is being made pursuant to a shelf registration statement filed with the SEC. The final terms will be disclosed in a final prospectus supplement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.66%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) provided an update on its portfolio and planned key milestones in 2024, including positive preliminary analysis of the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR), on-track enrollment for ulixacaltamide Phase 3 Studies, and a recently announced licensing partnership with Tenacia Biotechnology to develop and commercialize ulixacaltamide in Greater China with total consideration over $275 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.85%
Tags
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) announces a collaboration and license agreement with Tenacia Biotechnology (Shanghai) Company, Ltd. for the development and commercialization of ulixacaltamide for the treatment of essential tremor in Greater China. Praxis will receive upfront proceeds of $15 million and is eligible to receive up to $264 million in milestone payments as well as tiered royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.12%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines (PRAX) will present new patient data and updates on clinical progress for its epilepsy programs at upcoming meetings in Orlando, Florida. The company aims to discuss its potential impact on patients and families with the epilepsy community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am. The event will be available via live webcast through the company’s website. A replay of the webcast will be available for 90 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) Receives EMA's PRIME Designation for Elsunersen (PRAX-222) for SCN2A Gain of Function Developmental and Epileptic Encephalopathy (DEE)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. reported a corporate update and financial results for the third quarter 2023, with a cash balance of $101.1 million as of September 30, 2023, supporting runway into Q1 2025. The company initiated Essential3, the Phase 3 program for ulixacaltamide, and completed the final dosing for Part 1 of the EMBRAVE study for the treatment of pediatric patients with early-onset SCN2A-DEE. Praxis also expects topline results from the PRAX-628 Phase 2a proof-of-concept study in the fourth quarter of 2023 and from the PRAX-562 Phase 2 EMBOLD study in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.49%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. announced that management will participate in a panel discussion at the Truist Securities BioPharma Symposium on November 8, 2023. The event will be available via live webcast on the company's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
Rhea-AI Summary
Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for ulixacaltamide initiating this quarter with mADL11 as primary endpoint; nearly 600 patients have already expressed interest in participating.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
FAQ
What is the current stock price of Praxis Precision Medicines (PRAX)?
The current stock price of Praxis Precision Medicines (PRAX) is $77.6 as of January 23, 2025.
What is the market cap of Praxis Precision Medicines (PRAX)?
The market cap of Praxis Precision Medicines (PRAX) is approximately 1.5B.
What does Praxis Precision Medicines, Inc. specialize in?
Praxis specializes in developing therapies for CNS disorders characterized by neuronal imbalance, leveraging genetic insights for innovative treatments.
What are the primary product candidates of Praxis?
Praxis' key product candidates include Prax-114, Prax-944, Prax-562, Prax-222 (Elsunersen), PRAX-628, and Ulixacaltamide.
What is the status of Prax-114?
Prax-114 is in Phase IIa clinical trials for the treatment of major depressive disorder and perimenopausal depression.
How is Praxis advancing its epilepsy treatments?
Praxis is developing PRAX-562 and PRAX-628, with the latter showing strong potential as a best-in-class focal epilepsy treatment.
What are recent corporate milestones for Praxis?
Recent milestones include strategic partnerships, ongoing clinical trials, and financial progress ensuring operations funding into 2027.
Can you provide financial details on Praxis' operations?
As of the latest reports, Praxis has $243.3 million in cash, cash equivalents, and marketable securities, with funding expected to last into 2027.
How can I stay updated on Praxis' developments?
Visit https://www.praxismedicines.com and follow them on Facebook, LinkedIn, and Twitter/X for the latest updates.
What partnerships has Praxis recently announced?
Praxis recently partnered with Tenacia to extend ulixacaltamide's reach to Greater China and continues collaborations with Ionis Pharmaceuticals and RogCon, Inc.
What is Ulixacaltamide, and what is its current development stage?
Ulixacaltamide is a selective small molecule inhibitor for essential tremor, currently in late-stage development.
Where can I find more information about Praxis' clinical studies?
You can learn more about Praxis' clinical studies on their official website, www.praxismedicines.com, and specific study sites like www.praxisessentialtremor.com.
Praxis Precision Medicines, Inc.
Nasdaq:PRAX
PRAX Rankings
PRAX Stock Data
1.45B
17.29M
0.25%
103.89%
8.23%
Biotechnology
Pharmaceutical Preparations
United States of America
BOSTON